Volitionrx (VNRX) Research & Development (2011 - 2025)

Volitionrx has reported Research & Development for 11 years, with the latest figure at $2.5 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 4.61% year-over-year to $2.5 million; the trailing twelve-month figure through Dec 2025 stood at $10.1 million (down 30.02% YoY), and the FY2025 full-year result was $10.1 million, down 30.02% from the prior year.
• Research & Development for Q4 2025 stood at $2.5 million, up from $2.3 million in the prior quarter.
• The five-year high for Research & Development was $5.5 million in Q2 2023, with the low at $2.3 million in Q3 2025.
• Historically, Research & Development has averaged $3.6 million across 5 years, with a median of $3.6 million in 2021.
• Annual changes were most pronounced in 2023 — Research & Development soared 66.23% — and 2025, when it sank 43.68%.
• Volitionrx's Research & Development stood at $3.3 million in 2021, then advanced by 25.18% to $4.1 million in 2022, then rose by 10.02% to $4.5 million in 2023, then plunged by 43.06% to $2.6 million in 2024, then fell by 4.61% to $2.5 million in 2025.
• The last three Research & Development figures came in at $2.5 million (Q4 2025), $2.3 million (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.